GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker today…

A major Phase III clinical trial of a tau inhibitor aggregation therapy by Singapore's TauRx failed to meet its primary endpoint, though the work showed…

Eli Lilly & Co. CEO John Lechleiter is moving on. The outspoken CEO--who presided over a tumultuous period at Lilly, always promising a turnaround--will…

The Philadelphia host committee of the Democratic National Convention has hired a healthcare agency to manage its social media and digital this week--and …

Rebel Depomed investor Starboard Value wants a special meeting as soon as possible--and to get its wish, it’s taking matters into its own hands.

In its second Opdivo tie-up in as many days, Bristol-Myers Squibb has teamed up with Johnson & Johnson to test its drug in yet another variety of lung…

Looking for a bright spot in the gloom of Gilead Sciences’ second-quarter numbers? Look no further than its HIV franchise, where the latest generation of meds…

Earlier this month, Stada proposed a slate of four new directors--but now, as promised, its rebel shareholder is out with an alternative lineup.

Celgene’s best-selling drug Revlimid fell short in a lymphoma trial, putting its hopes for a $1 billion revenue boost in danger.